Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy (Q36379388)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

0 references

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy (English)

1 reference

Europe PubMed Central

13 August 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

Shashikant Srivastava

object named as

Shashikant Srivastava

2

0 references

object named as

Tawanda Gumbo

3

0 references

Jotam G Pasipanodya

1

object named as

Jotam G Pasipanodya

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

30 March 2012

1 reference

Europe PubMed Central

13 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

13 August 2017

55

1 reference

Europe PubMed Central

13 August 2017

169-177

1 reference

Europe PubMed Central

13 August 2017

2

1 reference

Europe PubMed Central

13 August 2017

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Bias due to misclassification in the estimation of relative risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

30 September 2017

Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

28 June 2018

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

21 September 2018

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

21 September 2018

The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3491771

5 December 2018

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of two regimens of intermittent thiacetazone plus isoniazid in the treatment of pulmonary tuberculosis in East Africa

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A study of two twice-weekly and a once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment 2. Second report: The results at 36 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis--a controlled trial of our regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic control of isoniazid metabolism in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22467670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/CID/CIS353

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36379388&oldid=2143263165"